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Abstract 
Most adults and adolescents with asthma require a preventer inhaler. In Australia these patients are often 
prescribed a combination inhaler containing a corticosteroid and a long-acting beta 2 agonist. These 
combination inhalers increase the cost of treatment for patients and for government and may not provide 
extra benefit. Many patients can control their asthma using an inhaled corticosteroid alone for prevention 
of symptoms and flare-ups. Most of the benefits of inhaled corticosteroids are obtained at low doses. To 
achieve these benefits it is important to check that the patient is using their inhaler correctly and regularly. 
Shared decision making includes discussing the options for treatment. Offering a more affordable 
preventer regimen could aid adherence and lead to improved outcomes. 
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The cost of asthma medicines
SUMMARY
Most adults and adolescents with asthma require a preventer inhaler. In Australia these patients 
are often prescribed a combination inhaler containing a corticosteroid and a long-acting 
beta2 agonist.
These combination inhalers increase the cost of treatment for patients and for government 
and may not provide extra benefit. Many patients can control their asthma using an inhaled 
corticosteroid alone for prevention of symptoms and flare-ups.
Most of the benefits of inhaled corticosteroids are obtained at low doses. To achieve these 
benefits it is important to check that the patient is using their inhaler correctly and regularly.
Shared decision making includes discussing the options for treatment. Offering a more affordable 
preventer regimen could aid adherence and lead to improved outcomes.
than inhaled corticosteroids and have a rapid effect. 
However, reliance on reliever inhalers, especially 
without a preventer, increases the risks of severe 
asthma exacerbations.6
Many clinicians are not aware that the average cost 
for patients with most low-dose corticosteroid-only 
preventers is substantially lower than treatment 
with a combination inhaled corticosteroid and 
long-acting beta2 agonist. There are several options 
for prescribing low-dose preventers for adults that 
give the lowest average monthly out-of-pocket cost 
for the patient. Consider the dose, the frequency 
of administration and the number of actuations 
(single metered doses) in each inhaler (see Table). 
When averaged over a year, the cost of a low-
dose inhaled corticosteroid can be strikingly low, 
as little as 15–30% of the out-of-pocket cost of any 
combination inhaler.
Inhaled corticosteroids are very effective – 
low dose and affordable cost do not mean 
low benefit
For most patients, 80–90% of the benefit of inhaled 
corticosteroids is obtained with low doses, if taken 
regularly and correctly. For example, in a large 
community study, the risk of dying of asthma was 
lower for patients who were dispensed four or more 
low-dose corticosteroid inhalers per year compared 
with those who received none.7 In a large randomised 
controlled trial, the risk of serious exacerbations 
(emergency department visits, hospitalisations, 
death) was also halved and symptoms were 
significantly reduced with regular use of budesonide 
400 micrograms/day, even in patients with symptoms 
as infrequent as once a week or less.8
Introduction
Australian guidelines recommend that most adults 
and adolescents with asthma should be taking a 
preventer inhaler. This is to minimise symptoms, 
prevent a decline in lung function, and to reduce the 
risk of exacerbations and asthma-related death.1 For 
the majority of patients, most of these benefits can 
be achieved with low-dose inhaled corticosteroids 
(e.g. beclometasone 200 micrograms/day, budesonide 
400 micrograms/day, ciclesonide 160 micrograms/day  
or fluticasone propionate 200 micrograms/day). 
However, in Australia, most patients are prescribed 
inhaled corticosteroids in combination with long-acting 
beta2 agonists,
2,3 often at moderate or high doses.2 
This is common practice, despite these combination 
products not being subsidised by the Pharmaceutical 
Benefits Scheme (PBS) for the initial treatment 
of asthma. 
Adherence is higher with combination inhalers 
than it is with inhaled corticosteroids alone. 
However, Australian data show that less than 20% 
of patients are being dispensed enough of either of 
these types of preventer inhaler to be taking their 
treatment regularly.2
Cost considerations
Out-of-pocket cost is a major factor contributing to 
poor adherence to treatment,4 including in Australia5 
where most medicines are subsidised by the PBS. 
Patients may not necessarily be comfortable 
telling a doctor their concerns about prescription 
costs, but pharmacists frequently see cost-related 
decisions being made at the point of purchase. This 
is particularly the case for asthma, since short-acting 
reliever inhalers, such as salbutamol, are cheaper 
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Using a preventer inhaler correctly reduces 
treatment costs
Patients can save costs by using their inhaler 
correctly. If their inhaler technique is incorrect, the 
drug is being wasted, as it does not reach the airways. 
This is the case for such a high proportion of patients 
(up to 80%) that inhaler technique can be assumed 
to be incorrect until proven otherwise. Health 
professionals need to know the correct technique 
for the type of inhaler being prescribed, and watch 
the patient using it. Clear step-by-step videos are 




Book a review visit if treatment has 
been started or changed
Patients usually start to feel the benefit from inhaled 
corticosteroids quite quickly, within 1–2 weeks, and 
they continue to improve for up to 18 months. If 
their asthma symptoms are still not controlled after 
2–3 months, check adherence and inhaler technique 
before considering stepping up treatment to a 
combination of a low-dose inhaled corticosteroid and 
a long-acting beta2 agonist. 
Combining a corticosteroid with a long-acting 
beta2 agonist reduces exacerbations on average 
by 20%. These can be reduced further if low-dose 
budesonide/formoterol (eformoterol) is prescribed 
as ‘maintenance and reliever therapy’, that is as both 
the patient’s regular maintenance inhaler (usually 
twice daily) and as their reliever inhaler (instead of 
salbutamol). However, contrary to expectations, 
adding a long-acting beta2 agonist has surprisingly 
little effect on the use of reliever inhalers.9 After 
asthma has been well-controlled for 2–3 months, 
treatment can be gradually stepped down to find the 
patient’s minimum effective dose.
Shared decision making improves 
asthma outcomes
Shared decision making, either when treatment is first 
discussed or at a review visit, improves adherence 
and asthma outcomes.10 As clinicians, we need to be 
aware of the contribution out-of-pocket costs have to 
patients’ day-to-day adherence, and to know the cost 
implications of what we prescribe. For some patients, 
offering a more affordable option may make the 
difference between their choosing to take a regular 
preventer inhaler, and ‘making do’ with a reliever 
alone, with the attendant risk of worse outcomes. 
Given the difference in cost, many patients may be 
interested in trying an inhaled corticosteroid-only 
inhaler first, rather than a combination inhaler, if the 
likely benefit and its time course are explained. 
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